Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. 1994

M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.

The complement receptor type 1 (CR1; CD35), carrying 30 short consensus repeats (SCRs), has two sites. Site 1 contains SCR-1 and SCR-2 and binds C4b. Site 2 contains SCR-8 and SCR-9 and was reported to bind mainly C3b (Klickstein, L. B., Bartow, T. J., Miletic, V., Rabson, L. D., Smith, J. A., and Fearon, D. T. (1988) J. Exp. Med. 168, 1699-1717). For the functional analysis we used two constructs, each with one site. CR1-4, composed of eight and one-half initial SCRs, carries site 1, binds C4b, and is cofactor for C4b cleavage. CR1-4(8,9), obtained from CR1-4 by converting site 1 to site 2, binds iC3/C3b and, unexpectedly, C4b. It is a cofactor for cleavage of both ligands. Its cofactor activity for C4b cleavage is greater than that of site 1. Analysis of the mutants constructed by interchanging homologous peptides between the two sites identified no sequences necessary for cofactor activity other than those required for binding. In site 2, peptides important for both ligands were found. Some modifications of either site led to higher activity for both ligands. Thus the activity of complement regulators can be increased by changing a few amino acids within SCRs, an important step toward the generation of more effective inhibitors of complement activation. Knowledge of the active sites of CR1 should be applicable to other SCR-containing proteins and should provide insights into the evolution of these proteins.

UI MeSH Term Description Entries
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006868 Hydrolysis The process of cleaving a chemical compound by the addition of a molecule of water.
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D016415 Sequence Alignment The arrangement of two or more amino acid or base sequences from an organism or organisms in such a way as to align areas of the sequences sharing common properties. The degree of relatedness or homology between the sequences is predicted computationally or statistically based on weights assigned to the elements aligned between the sequences. This in turn can serve as a potential indicator of the genetic relatedness between the organisms. Sequence Homology Determination,Determination, Sequence Homology,Alignment, Sequence,Alignments, Sequence,Determinations, Sequence Homology,Sequence Alignments,Sequence Homology Determinations
D017463 Receptors, Complement 3b Molecular sites on or in some B-lymphocytes and macrophages that recognize and combine with COMPLEMENT C3B. The primary structure of these receptors reveal that they contain transmembrane and cytoplasmic domains, with their extracellular portion composed entirely of thirty short consensus repeats each having 60 to 70 amino acids. Antigens, CD35,C3b Receptors,CD35 Antigens,CR1 Receptors,Complement 3b Receptors,Receptors, C3b,Receptors, CR1,CD 35 Antigens,CD35 Antigen,Complement 3b Receptor,Antigen, CD35,Antigens, CD 35,Receptor, Complement 3b

Related Publications

M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
January 1990, Current topics in microbiology and immunology,
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
November 1988, The Journal of experimental medicine,
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
April 2004, Molecular immunology,
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
January 1990, Journal of immunology (Baltimore, Md. : 1950),
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
January 1987, Methods in enzymology,
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
January 1999, Journal of biological regulators and homeostatic agents,
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
November 1997, Clinical and experimental immunology,
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
May 1992, Journal of biochemistry,
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
July 1989, Cellular immunology,
M Krych, and L Clemenza, and D Howdeshell, and R Hauhart, and D Hourcade, and J P Atkinson
January 1999, Molecular immunology,
Copied contents to your clipboard!